Phase I study shows positive clinical data from dose escalation of CAR T therapy in R/R B-NHL

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Intermountain Health is now offering a national expansion of CAR-T cell therapy, bringing cancer care closer to patients in southern Utah and Nevada.

May 16, 2025

Vol.51 No.19

Rewriting the rules of cancer treatment one nanobody at a time

I joined Translational Genomics Research Institute, part of City of Hope, late last year to launch the Center for Accelerated Nanotherapeutics.

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

The European Medicines Agency approved Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.

May 09, 2025

Vol.51 No.18

Clinical Roundup

USC team develops analytical tool to advance CAR T-cell therapy research

A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor T cells, including how they evolve during manufacturing and which ones are most effective at killing cancer.

May 02, 2025

Vol.51 No.17

Drugs & Targets

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.

May 02, 2025

Vol.51 No.17

Clinical Roundup

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Researchers with Memorial Sloan Kettering and City of Hope have created a tool that uses machine learning to assess a non-Hodgkin lymphoma patient’s likely response to chimeric antigen receptor T-cell therapy before starting the treatment, according to study results published on April 1 in Nature Medicine.

April 11, 2025

Vol.51 No.14

Phase I study shows positive clinical data from dose escalation of CAR T therapy in R/R B-NHL

YOU MAY BE INTERESTED IN

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Rewriting the rules of cancer treatment one nanobody at a time

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

USC team develops analytical tool to advance CAR T-cell therapy research

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login